Immunotherapy duo shows promise against advanced oral cancer
NCT ID NCT05681039
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether giving two immunotherapy drugs (tiragolumab and atezolizumab) before and after standard surgery and chemoradiation can help control advanced oral cancer. It includes 29 adults with newly diagnosed, stage 3-4 oral cavity squamous cell carcinoma that has a specific protein (PD-L1). The main goal is to see how many patients have a major reduction in tumor cells after the drugs.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ORAL CAVITY SQUAMOUS CELL CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
M D Anderson Cancer Center
Houston, Texas, 77030, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can Pre-Surgery immunotherapy prime the immune system to fight head and neck cancer?
- Glowing cancer cells: a new way to see tumors during surgery?
- Aiming to spare the neck: could smarter radiation cut side effects in oral cancer?
- Botox before the knife: could a Pre-Surgery injection lead to Better-Looking scars?
- Less neck surgery may be just as effective for oral cancer with one affected node
- Immunotherapy before surgery may cut skin cancer recurrence